@article{9625452dbfd2445e9f140862cabc32cb,
title = "Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model",
abstract = "Human killer cell immunoglobulin-like receptor, three Ig domains and long cytoplasmic tail (KIR3DL3) is expressed on natural killer (NK) cells and is a newly identified inhibitory receptor for B7 family member HERV-H LTR-associating protein 2 (HHLA2). Here, we summarize the isolation and expansion of KIR3DL3+ human NK cells, and in vitro functional characterization of in-house anti-KIR3DL3 monoclonal antibody (mAb). We also describe a human NK cell-based xenogeneic lung tumor model for testing the therapeutic activity of KIR3DL3 blockade in vivo. For complete details on the use and execution of this protocol, please refer to Wei et al. (2021).",
keywords = "Cancer, Cell Biology, Cell isolation, Cell-based Assays, Health Sciences, Immunology",
author = "Xiaoxin Ren and Corrigan, {Devin T.} and Xingxing Zang",
note = "Funding Information: This work was supported by funding from National Institutes of Health (NIH) R01CA175495 , Department of Defense PC210331 , and Price Family Foundation Award awarded to X.Z. We thank Flow Cytometry Core Facility that was supported by the NIH P30CA013330 (Montefiore Einstein Cancer Center) and IVIS Core Facility for in vivo imaging. We greatly acknowledge the assistance of former lab member Dr. Yao Wei in developing this protocol. Funding Information: This work was supported by funding from National Institutes of Health (NIH) R01CA175495, Department of Defense PC210331, and Price Family Foundation Award awarded to X.Z. We thank Flow Cytometry Core Facility that was supported by the NIH P30CA013330 (Montefiore Einstein Cancer Center) and IVIS Core Facility for in vivo imaging. We greatly acknowledge the assistance of former lab member Dr. Yao Wei in developing this protocol. X.R. and D.C. designed and conducted experiments, analyzed data, and wrote the first draft of the manuscript. X.Z. reviewed and edited the manuscript, acquired funding, and supervised the study. X.R. and X.Z. are inventors of a pending patent (KIR3DL3 is an inhibitory receptor of the immune system and uses thereof). X.Z. is an inventor of two granted patents (HHLA2 as a novel inhibitor of human immune system and uses thereof; TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies). X.Z. is a scientific co-founder of NextPoint Therapeutics. Publisher Copyright: {\textcopyright} 2022 The Author(s)",
year = "2022",
month = dec,
day = "16",
doi = "10.1016/j.xpro.2022.101818",
language = "English (US)",
volume = "3",
journal = "STAR Protocols",
issn = "2666-1667",
publisher = "Cell Press",
number = "4",
}
